Antibody-drug conjugates (ADCs) have achieved commercial success over the last ten years. ADCs offer the prospect of more precise treatments and a reduction in off-target effects, however challenges such as conjugate instability impact efficacy and the therapeutic window. Additionally, manufacturing processes for some ADC configurations were not viable for commercial scale and early achievements in bloodborne cancer were not mirrored in the treatment of solid tumors. There has been significant evolution in the ADC space driven in part by innovations, including Catalent’s award-winning SMARTag® ADC platform.
In this webinar, Chemistry Nobel Laureate, Carolyn Bertozzi, Ph.D., Professor, Stanford University, Penelope Drake, Ph.D., Head of R&D, Bioconjugates, Catalent Biologics, and Seema Kantak, Ph.D., Senior Vice President, Biotherapeutics, Exelixis, will discuss the latest trends in ADC discovery and development. Their conversation will focus on how next generation pipelines are being shaped by payload and linker-chemistry innovations, including the SMARTag platform. The platform originated in Dr. Bertozzi’s lab and has been shown to develop stable conjugates with an expanded therapeutic window.
Join the webinar to hear the panelists’ perspectives on the ADC market and how innovations like the SMARTag technology are improving therapies for patients.
Key Learning Objectives:
- The current state of the ADC market
- The evolution of the SMARTag technology from lab to best-in-class ADCs
- How innovations in payload and linker-chemistries have impacted ADC stability and efficacy
